CAPLIPOINTCaplin Point Laboratories Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 19.0% YoY
- • Profit growth: 19.4% YoY
- • ROE: 19.9%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 34
- • RSI Oversold Reversal signal (setup quality 54%)
Bull case
- • Revenue growth: 19.0% YoY
- • Profit growth: 19.4% YoY
- • ROE: 19.9%
- • Price vs SMA200: above
Bear case
- • Dividend yield: 0.27%
- • RSI: 33
- • MACD: bearish
- • 1-month return: -20.7%
Key risks
- • Momentum is fading versus the broader market
- • Dividend yield: 0.27%
- • RSI: 33
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹93.14). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.